Urothelial bladder cancer (UBC) is heterogeneous at the clinical, pathological and genetic levels. Tumor invasiveness (T)
and grade (G) are the main factors associated with outcome and determine patient management 1 . A discovery exome sequencing screen (n = 17), followed by a prevalence screen (n = 60), identified new genes mutated in this tumor coding for proteins involved in chromatin modification (MLL2, ASXL2 and BPTF), cell division (STAG2, SMC1A and SMC1B) and DNA repair (ATM, ERCC2 and FANCA). STAG2, a subunit of cohesin, was significantly and commonly mutated or lost in UBC, mainly in tumors of low stage or grade, and its loss was associated with improved outcome. Loss of expression was often observed in chromosomally stable tumors, and STAG2 knockdown in bladder cancer cells did not increase aneuploidy. STAG2 reintroduction in non-expressing cells led to reduced colony formation. Our findings indicate that STAG2 is a new UBC tumor suppressor acting through mechanisms that are different from its role in preventing aneuploidy.
The most commonly mutated oncogene in UBC is FGFR3 (50-60% of cases): mutations are more frequent in non-muscle-invasive bladder cancers (NMIBCs) with a low risk of progression (stage Ta lowgrade tumors), here designated 'non-aggressive' (Online Methods) 2, 3 . PIK3CA mutations occur in 15-20% of tumors and tend to associate with FGFR3 mutations 4 . p53 and RB pathway inactivation has been associated with NMIBCs with a high risk of progression (stage Ta or T1 high-grade tumors) and with muscle-invasive bladder cancer (MIBC) (here designated 'aggressive') 5, 6 . RAS mutations are less common and are mutually exclusive with FGFR3 mutations 7 . There is now extensive evidence indicating that NMIBCs of high grade are genomically similar to MIBCs 8, 9 : non-aggressive UBCs are genomically stable, whereas aggressive UBCs are genomically unstable 2, [8] [9] [10] . Recently, exome sequencing has identified chromatin remodeling as an important pathway involved in UBCs 11 ; this study focused mainly on MIBCs.
To discover new genes mutated in UBC, we sequenced the exomes of 17 tumors of variable stage and grade and corresponding normal leukocyte DNA; all neoplastic samples used had a tumor cellularity of ≥70% (Supplementary Table 1 ). Because there are major initiatives for the sequencing of MIBC (for example, The Cancer Genome Atlas (TCGA) project), we have focused mainly on NMIBC. Metrics for enrichment and depth of coverage are shown in Supplementary Table 2: the mean coverage for tumors and leukocytes was 79 ± 16 × and 82 ± 18 ×, respectively. We identified 2,927 somatic mutations, of which 1,263 and 798 were predicted to be relevant (nonsynonymous) and damaging (have a functional effect) (Supplementary Table 3 ), respectively (Online Methods). The average number of somatic mutations per tumor was 169 ± 114, with wide interindividual variation (range of 4-360 mutations) (Fig. 1a) , a figure that falls in the midrange for exome studies in solid tumors in adults. C>T transitions were the most common nucleotide substitution (mean of 44%), followed by C>G transversions (Fig. 1b) . The ratio of Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy nonsynonymous to synonymous (NS:S) changes was <1 in 15 of 17 samples ( Fig. 1c and Supplementary Fig. 1a) . We compared the total number of single-nucleotide variants (SNVs), indels, transitions, transversions, synonymous mutations, non-damaging nonsynonymous mutations and damaging nonsynonymous mutations in aggressive versus non-aggressive tumors; all variables were highly similar in both tumor groups. We performed the same analysis according to smoking status: the number of damaging mutations was higher in tumors from smokers than in those from non-smokers, but differences did not reach statistical significance (P = 0.09). The number of mutations in tumors from individuals who were >60 years old was also slightly but not significantly higher than for younger individuals (Supplementary Fig. 2 ). The NS:S ratio was similar regardless of tumor aggressiveness and smoking status, but this ratio was slightly lower in individuals diagnosed at >60 years of age ( Supplementary  Fig. 1b ). It will be necessary to sequence more tumors to further investigate these relationships.
We assessed the reliability of the exome analysis and strategies for somatic variant calling using Sanger sequencing: we assayed 226 variants and verified 219, of which 214 (94.7%) were confirmed to be somatic (Supplementary Table 3 ). The list of genes with nonsynonymous mutations in ≥3 tumors that were expressed in >30% of UBCs, on the basis of Affymetrix expression analyses of an independent tumor sample series (n = 43) covering the full spectrum of the disease, is shown in Table 1 . Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses identified chromatin modification, DNA repair and DNA damage response, apoptosis and the cell cycle among the most significant processes to which mutated genes were ascribed (false discovery rate (FDR) < 0.1) (Supplementary Table 4) .
To extend our findings, we performed a mutation prevalence screen including mainly NMIBCs (n = 60 tumors) (Supplementary Table 5 ) using the HaloPlex Target Enrichment System followed by sequencing. We included selected genes that were recurrently mutated in the discovery screen as well as additional genes from the pathways in which these genes participate (Supplementary Table 6 ). We identified 260 SNVs: 200 were predicted to be relevant, and 143 of these were predicted to be damaging. We analyzed 95 mutations identified by HaloPlex by Sanger sequencing; 73 were verified (76.13%), and 72 of these (98.6%) were confirmed to be somatic.
The joint distribution of mutations in the discovery and prevalence screens is shown in Figure 2 and Table 1 . Among the genes recurrently mutated, we identify new genes involved in chromatin remodeling different from those reported by Gui et al. 11 (MLL2, ASXL2 and BPTF). The BPTF protein binds histone H3 that is trimethylated at lysine 4 (H3K4me3) and has been found to be mutated in hepatocarcinoma 12 , but little is known about its function in cancer. We show that BPTF knockdown led to a marked reduction in colony formation in the three UBC lines tested (Supplementary Fig. 3 ), suggesting that it has a role in cancer cell proliferation. We confirmed recurrent mutations in ARID1A, KDM6A (UTX), CREBBP, EP300, MLL and MLL3 (ref. 11), in agreement with recent reports implicating mutations in a wide range of chromatin remodelers in human cancer [12] [13] [14] [15] . Notably, we identified recurrent, previously unreported somatic mutations in genes involved in DNA repair (ATM, ERCC2 and FANCA, among others) and in the cohesin subunits STAG2, STAG1, SMC1A and SMC1B, indicating that these pathways have an important role in UBC. FGFR3, TP53, PIK3CA and RB1 are among the recurrently mutated genes, providing evidence of the representativeness of the tumors analyzed.
We have focused on STAG2 because it was significantly mutated in our exomes ( Table 1) ; an additional mutation was found in 9 published UBC exomes 11 , and we identified 2 mutations in 21 MIBC exomes from the TCGA project (overall damaging mutation rate of 13% (6/47)). Our prevalence screen identified nine additional somatic mutations predicted to be damaging. Altogether, we have identified damaging somatic STAG2 mutations in 12 of 77 tumors (15.6%; 5 nonsense, 4 exon junction, 2 missense and 1 indel) ( Supplementary Fig. 4 and Supplementary Table 7), and 9 of 11 were verified by Sanger sequencing (Supplementary Fig. 5 ). Damaging mutations were found in both non-aggressive (6/29; 20.7%) and aggressive (5/47; 10.6%) tumors. STAG2-inactivating mutations leading to loss of protein expression have recently been reported in non-epithelial tumors 16 . STAG2 expression was low or undetectable in 6 of 7 (85%) UBCs with damaging mutations and in 3 of 34 (9%) tumors with wild-type STAG2 (P = 0.0001) (Fig. 3, Supplementary Fig. 5 and Supplementary Table 7) . Together with the exome significance analysis, these data indicate that STAG2 is a new gene commonly mutated in UBC.
We then analyzed STAG2 expression in tissue microarrays of incident tumors representative of the disease spectrum ( Supplementary  Tables 8 and 9 ) 3, 17 . Loss of STAG2 expression in tumors, defined as a histoscore of ≤50 with detectable stromal expression, was observed in 197 of 671 tumors (29.3%) ( Fig. 3 and Supplementary Fig. 5 ). Loss of STAG2 expression was significantly associated with multicentricity (P = 0.011), tumor size (P = 0.002), low stage (P = 5.7 × 10 −15 ) and low grade (P = 1.96 × 10 −15 ) (Supplementary Table 10) . Abnormal l e t t e r s npg l e t t e r s STAG2 expression patterns included focal losses within otherwise positive tumors and a predominant cytoplasmic distribution of the protein (Supplementary Fig. 6 ). Because non-aggressive tumors are more differentiated, lack of STAG2 might reflect urothelial cell maturation. Arguing against this possibility, STAG2 expression was detected in all cell layers of the normal urothelium ( Supplementary Fig. 7 ). We also analyzed whether mechanisms other than mutation might account for loss of STAG2 expression. Using SNP arrays, we found STAG2 losses in 1 of 18 TaG1 or TaG2 STAG2-negative tumors (5%) from male subjects. Similar findings have been reported in leukemia 16, [18] [19] [20] ( Supplementary Fig. 8 ).
STAG2 encodes a subunit of cohesin, a complex that mediates sister chromatid cohesion to ensure accurate chromosome segregation and DNA repair. Cohesin also regulates gene expression through mechanisms involving DNA looping and interactions with transcriptional regulators such as Mediator and CTCF 21, 22 . Somatic human cells contain two versions of this complex consisting of SMC1A, SMC3, RAD21 and either STAG2 or STAG1 (ref. 21 ). Although there is still an incomplete understanding of the functional redundancy of these complexes, differential roles in centromeric versus telomeric cohesion have been proposed, and STAG1 has been preferentially implicated in transcriptional control 23, 24 . Using immunohistochemistry, we showed that STAG1 is expressed in the normal urothelium and in the majority of UBCs, including most tumors lacking STAG2 expression (Supplementary Figs. 7 and 9). Interestingly, all six tumors that lost both STAG1 and STAG2 expression were of high grade and were wild type for FGFR3, suggesting partial functional compensation in the maintenance of integral chromosome segregation machinery. The more frequent loss of the expression of STAG2 in tumors ( Supplementary Fig. 9a ) may reflect the fact that only one hit is required for its inactivation, given its location on the X chromosome.
Recently, STAG2 mutations in glioblastoma, melanoma and Ewing sarcoma have been proposed to participate in tumor development by promoting aneuploidy 16 . This hypothesis is at odds with our finding Data are shown for the discovery screen and the prevalence screen. Discrepancies between number of mutations and numbers of mutant tumors result from the occurrence of ≥2 mutations in the same gene in a given tumor sample. NA, not available.
a P-value calculations are based on the mutations identified in the discovery screen (Online Methods). b One sample with a mutation in STAG2 is excluded from the non-aggressive versus aggressive tumor comparison owing to insufficient information for classification. c P value for the frequency of mutant tumors with non-aggressive versus aggressive features. STAG2  CREBBP  TP53  MLL2  ARID1A  KDM6A  PIK3CA  ATM  BRAF  EP300  ERCC2  MAPK8IP3  MYCBP2  FANCA  RB1  n events  Aggressiveness  Smoking status   418  427  088  435  339  473  Esp21  413  344  479  533  433  718  Esp104  Esp27  193  451  331  311  281  414  274  489  424  131  Esp44  080  251  207  313  064  343  Esp66  147  416  116  188  310  439  121  432  076  272  508  818  179  304  438  497  358  047  Esp86  181  453  375  062  114  011  102  248  275  280  308  312  325  395  402  411  450  597  630  512  562  639  776  811  823 Figure 2 Distribution of mutations in genes recurrently mutated in UBC that are expressed in >30% of tumors: joint analysis of the discovery and prevalence screens. In 22 of 77 tumors (28.6%), none of the genes listed were found to be mutated. For aggressiveness, red indicates aggressive tumors, and blue indicates non-aggressive tumors. Aggressiveness was defined as described in the Online Methods. For smoking status, red indicates smokers, and blue indicates non-smokers. White squares indicate cases where information was not available.
npg l e t t e r s that loss of STAG2 expression occurs mainly in non-aggressive UBCs that are genomically stable. To address this issue, we analyzed chromosome number changes in a panel of 23 TaG1 and TaG2 tumors using high-resolution SNP or BAC arrays. Of 11 tumors without STAG2 expression, 9 lacked aneuploidy, and 2 showed loss of 1 copy of chromosome 9; similarly, 9 of 12 tumors that expressed STAG2 had normal chromosomal content (Fig. 4a, Supplementary Fig. 10 and Supplementary Table 11 ). Consistent with these findings, mutations in STAG2 and other cohesin genes have recently been reported not to be associated with aneuploidy in acute myeloid leukemia [18] [19] [20] . We next knocked down STAG2 in three UBC lines displaying a broad range of phenotypes. Efficient knockdown was achieved in the three lines, but there were no consistent effects on chromosome number at metaphase (Fig. 4b,c, Supplementary Fig. 11 and Supplementary Table 12) , unlike what was previously reported in HCT116 cells 16 . This discrepancy may reflect the fact that different cell types have variable tolerance to aneuploidy. We also introduced STAG2 cDNA in three cell lines lacking STAG2 protein expression: UM-UC-6 cells harbor a p.Arg305* stop-gain alteration (exon 11) and a p.Phe1228Leu alteration (exon 33), VM-CUB-3 cells harbor a 10-bp deletion in exon 6 and LGW0 1 G600 cells have wild-type sequence in exons 3-35. In the three cell lines, we observed a significant decrease in colony formation upon STAG2 lentiviral expression ( Fig. 4d and Supplementary Fig. 12 ). Intriguingly, STAG2 knockdown was also associated with reduced colony formation in five different cell lines (Supplementary Fig. 13 ). Similar effects have been reported with knockdown of the tumor suppressor ARID1A in pancreatic and bladder cancer cells 25, 26 .
To place these findings in the context of the known pathways of UBC progression, we assessed the association of STAG2 alterations with FGFR3 mutation or overexpression, p53 nuclear accumulation and Ki67 expression (Supplementary Tables 13-16) 2 . In NMIBC, loss of STAG2 was significantly more common in tumors with mutant FGFR3 (42.7% versus 27.2%; P = 0.001), tumors lacking p53 overexpression (P = 0.002) and tumors with a low Ki67 index (P = 0.002). These results indicate that loss of STAG2 is associated with less aggressive tumors. Within the low-risk NMIBC subgroup, loss of STAG2 expression was associated with FGFR3 mutant status (P = 0.059) and with low p53 expression (P = 0.011). In individuals with high-risk NMIBC, loss of STAG2 expression was associated with high FGFR3 expression (P = 0.037), FGFR3 mutation (P = 0.12) and a low Ki67 index (P = 0.049). In both high-risk NMIBC and MIBC, there was no association with p53 expression as detected by immunohistochemistry (Supplementary Tables 13-16 ).
We then analyzed the association of loss of STAG2 expression with recurrence and progression among individuals with NMIBC and with progression and mortality in individuals with MIBC. We applied both Kaplan-Meier curves and multivariable Cox regression analyses. The large sample size of our study allowed us to perform a more informative stratified analysis. Loss of STAG2 expression was associated with lower risk of tumor recurrence and progression in individuals with NMIBC (Fig. 5a,b) . However, in multivariable analyses, STAG2 expression was not an independent predictor of recurrence or progression after adjusting for stage, grade and FGFR3 mutation status (Supplementary  Tables 17 and 18 
e t t e r s
(hazards ratio (HR) = 0.68; P = 0.244), and it was an independent predictor of survival in the multivariable analysis (HR = 0.44; P = 0.018) (Fig. 5c,d and Supplementary Tables 19 and 20) . Therefore, we conclude that loss of STAG2 expression is associated with better prognosis in individuals with both NMIBC and in MIBC; additional studies are required to determine its clinical value. In summary, we find that both previously reported and newly identified genes coding for proteins involved in chromatin modification are recurrently mutated in UBC. In addition, we identify mutations in genes involved in the cell cycle, DNA repair and the regulation of apoptosis. The frequent alteration of genes in these pathways may provide opportunities for novel therapies, including those based on synthetic lethality. STAG2 is significantly mutated in UBC; mutations and loss of expression are common, particularly in tumors of low stage and grade, and are associated with improved clinical outcome. In non-aggressive tumors, STAG2 alterations occur in the absence of chromosomal instability. Our findings strongly suggest that STAG2 is a new tumor suppressor in UBC through mechanisms that are distinct from its role in cohesion to prevent aneuploidy. Tables 1 and 5 ). STAG2 expression was analyzed using tissue microarrays containing tumors from the Epicuro/SBCS, including tumors from individuals with newly diagnosed UBC. Staging, grading and follow-up were performed as described 3, 17 . Expert pathologists reviewed diagnostic slides from all tumor blocks. We categorized TaG1 and TaG2 tumors as low-risk NMIBC or non-aggressive; TaG3, T1G2 and T1G3 tumors were categorized as high-risk NMIBC; and ≥T2 tumors were categorized as MIBC. The latter two groups were pooled as aggressive tumors. Subject characteristics are summarized in Supplementary Tables 8 and 9 . In subjects with NMIBC, recurrence was defined as the reappearance of NMIBC following a negative follow-up medical evaluation. Progression was defined as a transition from NMIBC to MIBC or the development of new local or metastatic tumors after primary treatment for individuals with MIBC. Median follow-up time was 62.6 months (range of 1-98 months). All deaths were recorded, but only UBC-related deaths were considered for survival analysis. Cases dying from other causes were censored at the time of death. Survival was computed as the period comprised between diagnosis and death or last control. All subjects provided written informed consent 3 . The ethics committees of all participating institutions approved both studies. Base calling and quality control were performed on the Illumina Real-Time Analysis pipeline. Sequence reads were trimmed to the first base with quality >10 that mapped to human genome build hg19 (GRCh37) using GEM, allowing ≤4 mismatches. Reads not mapped by Genome Multitool Mapper (GEM) 27 (~4%) were submitted to a last round of mapping with BFAST. Results were merged; only uniquely mapping, non-duplicate read pairs were used. SAMtools suite version 0.1.18 with default settings was used to call SNVs and short indels. Variants on regions with low mappability, read depth <10, tail distance bias P < 0.05 or strand bias P < 0.001 were filtered out. Somatic mutations were called by comparing tumor and blood exomes; Fisher's exact tests were performed using variant-supporting read counts. Only variants with Fisher's exact test P value <0.0001 were considered.
All SNVs in exon junctions or that led to a nonsynonymous change were considered to be 'relevant' . SNVs that led to an amino acid substitution were evaluated using MutationAssessor 28 and SIFT 29 to predict their damaging effect; both scores were normalized into a range from 0 to 1. P values from SIFT were subtracted from 1. MutationAssessor predictions were scored as follows: high risk of damage was assigned 1, medium risk of damage was assigned 0.7 and low risk of damage was assigned 0.5. When both predictions were available, scores were averaged; if one prediction was missing, the other score was used. Variants with a final score of >0.8 were considered to be damaging. Stop gains and frameshifts were considered to be damaging if they ablated >30% of the sequence or a protein domain annotated in InterPro. Variants close to an exon boundary were considered to be relevant and damaging if the distance from the exon junction was eight bases into the intron or two bases into the exon of donor junctions or if the distance from the exon junction was eight bases into the intron or three bases into the exon of acceptor junctions. Scores from both methods were used as input to calculate P value for the associated genes. We used the Oncodrive-fm approach 30 that combines data on recurrence and functional impact ( Table 1) .
Statistical analyses within R software (2.15.1) were performed on stage, smoking status and age groups using Mann-Whitney U tests (Fig. 1) . Fisher's exact tests (non-aggressive versus aggressive) were performed for recurrently altered genes ( Table 1) ; P value <0.05 was considered to be statistically significant.
Pathway analysis was performed as reported 31 . First, a gene list was selected. We processed different combinations of three lists: (i) all relevant genes (those with mutations leading to nonsynonymous substitutions or affecting exon junctions); (ii) damaged genes (those with mutations predicted to be damaging); and (iii) recurrently altered genes (those with relevant mutations in ≥2 samples). The resulting lists were examined for enrichment in terms from Gene Ontology (biological process) and KEGG pathways. For the latter, pathways associated with diseases were filtered out, as reported 32 . Enrichment analysis was based on a hypergeometric test. P values were adjusted using Benjamini-Hochberg's FDR; only FDR < 0.1 was considered. A correction for genes in overlapping clusters was applied.
For targeted resequencing, the HaloPlex Target Enrichment System (Agilent) was used in an independent tumor series (n = 60) following the manufacturer's instructions. Five cases from the discovery screen were included for targeted resequencing. A library of genomic DNA fragments was created by digestion in eight restriction reactions and was hybridized with probes against target regions incorporating Illumina paired-end sequencing motifs and index sequences. DNA was captured and PCR amplified with KAPA HiFi HotStart polymerase or Herculase II Fusion Enzyme, and products were purified using AMPure XP beads. Amplicons were sequenced in multiplex using Illumina protocols. Adaptors and primers were removed from both ends of the reads with FAR. Trimmed reads were mapped; SNPs and indels were called as described above, without excluding duplicates and filtering out variants with tail distance bias P < 0.05 or strand bias P < 0.001. Variants outside of the regions selected for enrichment, with low mappability, with read depth of <10, occurring in >1% of the reads in blood or annotated in the 1000 Genomes Project as SNPs (release 20110521) were filtered out. Variants with Fisher's exact test P value for somatic comparison <0.0001 were considered. Somatic mutations were called by comparing tumor and blood samples. Damaging and effect annotations were performed as described for exomes.
Mutations were verified by Sanger sequencing. Using this bioinformatics pipeline, we verified 94.7% of the SNVs called as somatic mutations by exome sequencing.
STAG2 sequencing of UBC lines. Cell lines were obtained from the American Type Culture Collection or from the investigators who established them and were authenticated by gene mutation analyses; all cultures were mycoplasma free. Exons 3-7, 11-31 and 33-35 of STAG2 were sequenced from overlapping amplicons generated from cDNA; exons 8-10 were sequenced from genomic DNA. The predominant transcript lacked exon 32 (Ensembl variant STAG2-0001) and coded for a 1,231-residue protein.
Immunohistochemistry. STAG2 was detected using clone J-12 (0.5 µg/ml) (Santa Cruz Biotechnology, sc-81852) and affinity-purified rabbit polyclonal antibodies (0.5 µg/ml) raised against a synthetic peptide (DPASIMDESVLGVSMF) 23 . Both antibodies yielded concordant results in 92% of tumors. To detect STAG1, we used affinity-purified rabbit polyclonal antibodies (2 µg/ml) raised against a synthetic peptide (EDDSGFGMPMF) 23 . Antibodies D5/16B4 (1:2,000 dilution) and Ks20.8 (1:50 dilution) detecting KRT5/KRT6 and KRT20, respectively, were from Dako. Antigen retrieval and reactions were performed as described 6, 17 . A histoscore was calculated as the product of the staining intensity (0-3) and the percentage of positive cells (0-100%). Unsupervised clustering analysis was performed using scores and the heatmap.2 function of the gplots package within the R 2.15.1 statistical environment.
Gene copy number analyses. Copy number changes were analyzed using manually microdissected fresh tissue samples containing ≥60% tumor cells (n = 55). DNA was hybridized to Illumina HumanHap 1M BeadChip SNP arrays; 20 tumors were TaG1 or TaG2. Copy number changes were called as described 33 . An additional 76 samples were analyzed using Human 2.0 BAC arrays (UCSF Cancer Center) 10, 34 .
STAG2 functional assays.
To knock down STAG2, control or STAG2-targeting lentiviral particles were produced in HEK293T cells using Sigma Mission plasmids. Viral supernatants were used to infect RT112, UM-UC-5, 639V, SW1710 and UM-UC-11 cells; after three rounds of infection with shRNA-encoding lentiviruses, cells were selected for 48 h in medium containing puromycin (2 µg/ml). To overexpress STAG2, human cDNA (b isoform; 1,231 residues) was amplified by PCR (Addgene pEGFP-STAG2 plasmid, ref. 31972) and subcloned into the pLVX-puro lentiviral vector. After three rounds of infection, npg
